Helen Wu

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Chris Parker, Noel W. Clarke, Adrian Cook et al. · The Lancet · 2024 · 49 citations · Full text

Medicine, Oncology, Surgery +15

KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Evan Y. Yu, Josep M. Piulats, Gwénaëlle Gravis et al. · Journal of Clinical Oncology · 2020 · 39 citations

Pharmacy, Oncology, Pharmacotherapy +15

Functional outcome after stroke in patients with rheumatoid arthritis and systemic lupus erythematosus

Tracy U. Nguyen‐Oghalai, Helen Wu, Terry A. McNearney et al. · Arthritis Care & Research · 2008 · 24 citations · Full text

Medicine, Neurology, Rehabilitation Medicine +17

Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5.

Julie N. Graff, Emmanuel S. Antonarakis, Christopher Hoimes et al. · Journal of Clinical Oncology · 2020 · 24 citations

Pharmacy, Oncology, Pharmacotherapy +16

KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

William L. Berry, Peter C.C. Fong, Josep M. Piulats et al. · Journal of Clinical Oncology · 2020 · 16 citations

Medicine, Oncology, Pharmacology +14